Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 477
- Registration Number
- NCT00412737
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT00412217
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00412334
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT00408213
A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT00404703
A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT00400439
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00400361
A Study of R547 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT00400296
The Effect Of Oral Ibandronate In Male Osteoporosis
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2009-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT00397839
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT00394953
© Copyright 2024. All Rights Reserved by MedPath